$151 Million is the total value of Ally Bridge Group (NY) LLC's 39 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 204.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | New | SEAGEN INC | $12,658,000 | – | 92,506 | +100.0% | 8.36% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $8,989,000 | – | 217,075 | +100.0% | 5.94% | – |
| SNY | New | SANOFIsponsored adr | $8,745,000 | – | 230,000 | +100.0% | 5.77% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $8,346,000 | – | 1,528,580 | +100.0% | 5.51% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $7,693,000 | – | 742,570 | +100.0% | 5.08% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $7,653,000 | – | 479,506 | +100.0% | 5.05% | – |
| New | GSK PLCsponsored adr | $7,505,000 | – | 255,000 | +100.0% | 4.96% | – | |
| AMRN | New | AMARIN CORP PLCspons adr new | $6,931,000 | – | 6,358,288 | +100.0% | 4.58% | – |
| ALKS | New | ALKERMES PLC | $6,699,000 | – | 300,000 | +100.0% | 4.42% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $6,297,000 | – | 931,539 | +100.0% | 4.16% | – |
| New | SYROS PHARMACEUTICALS INC | $5,593,000 | – | 868,403 | +100.0% | 3.69% | – | |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $4,596,000 | – | 74,262 | +100.0% | 3.03% | – |
| MDVL | MEDAVAIL HOLDINGS INC | $4,574,000 | -49.3% | 5,894,897 | 0.0% | 3.02% | -63.3% | |
| GOSS | Sell | GOSSAMER BIO INC | $4,516,000 | -22.9% | 377,000 | -46.1% | 2.98% | -44.2% |
| SANA | New | SANA BIOTECHNOLOGY INC | $4,412,000 | – | 735,250 | +100.0% | 2.91% | – |
| ARGX | Sell | ARGENX SEsponsored adr | $4,321,000 | -71.0% | 12,240 | -68.9% | 2.85% | -79.0% |
| SAGE | New | SAGE THERAPEUTICS INC | $4,316,000 | – | 110,222 | +100.0% | 2.85% | – |
| ALLK | New | ALLAKOS INC | $3,661,000 | – | 598,172 | +100.0% | 2.42% | – |
| ACET | New | ADICET BIO INC | $3,475,000 | – | 244,400 | +100.0% | 2.29% | – |
| GLPG | New | GALAPAGOS NVspon adr | $3,261,000 | – | 76,489 | +100.0% | 2.15% | – |
| RGEN | New | REPLIGEN CORP | $3,129,000 | – | 16,724 | +100.0% | 2.07% | – |
| COGT | Sell | COGENT BIOSCIENCES INC | $3,044,000 | -60.6% | 204,014 | -76.2% | 2.01% | -71.5% |
| Sell | ISOPLEXIS CORP | $2,618,000 | -26.5% | 1,522,364 | -7.7% | 1.73% | -46.8% | |
| RAPID MICRO BIOSYSTEMS INC | $2,260,000 | -24.9% | 699,664 | 0.0% | 1.49% | -45.6% | ||
| AVIR | New | ATEA PHARMACEUTICALS INC | $2,048,000 | – | 360,000 | +100.0% | 1.35% | – |
| Sell | SCIENCE 37 HOLDINGS INC | $2,039,000 | -28.1% | 1,266,512 | -10.2% | 1.35% | -47.9% | |
| New | AADI BIOSCIENCE INC | $1,761,000 | – | 124,625 | +100.0% | 1.16% | – | |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $1,747,000 | -39.9% | 823,974 | -23.7% | 1.15% | -56.5% |
| INCY | New | INCYTE CORP | $1,666,000 | – | 25,000 | +100.0% | 1.10% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $1,395,000 | – | 100,000 | +100.0% | 0.92% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $1,385,000 | – | 432,952 | +100.0% | 0.91% | – |
| VOR | New | VOR BIOPHARMA INC | $1,016,000 | – | 255,162 | +100.0% | 0.67% | – |
| EDIT | New | EDITAS MEDICINE INC | $1,015,000 | – | 82,900 | +100.0% | 0.67% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $635,000 | – | 533,501 | +100.0% | 0.42% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $548,000 | – | 334,255 | +100.0% | 0.36% | – |
| MOR | New | MORPHOSYS AGsponsored ads | $478,000 | – | 95,031 | +100.0% | 0.32% | – |
| CRIS | New | CURIS INC | $185,000 | – | 264,023 | +100.0% | 0.12% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $152,000 | – | 64,295 | +100.0% | 0.10% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $103,000 | – | 86,242 | +100.0% | 0.07% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -1.52% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -175,000 | -100.0% | -2.11% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -160,000 | -100.0% | -2.77% | – |
| Exit | DICE THERAPEUTICS INC | $0 | – | -207,290 | -100.0% | -2.93% | – | |
| SYRS | Exit | SYROS PHARMACEUTICALS INC | $0 | – | -3,364,895 | -100.0% | -2.95% | – |
| Exit | SOMALOGIC INC | $0 | – | -735,000 | -100.0% | -3.03% | – | |
| NUVB | Exit | NUVATION BIO INC | $0 | – | -1,137,152 | -100.0% | -3.36% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -3.98% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -170,000 | -100.0% | -4.10% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -181,500 | -100.0% | -4.10% | – |
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -496,012 | -100.0% | -5.23% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -650,000 | -100.0% | -5.70% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -160,000 | -100.0% | -5.88% | – |
| LNTH | Exit | LANTHEUS HLDGS INC | $0 | – | -115,000 | -100.0% | -6.92% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.